Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
OBJECTIVE
Different cost-effectiveness analyses have been presented for interferon beta-1b (IFNB) in the treatment of secondary progressive multiple sclerosis (SPMS). All studies have used modeling techniques since any effect on progression of disability achieved during a clinical trial will last beyond the trial. Different approaches to extrapolation have been taken, but generally they have been based on disease progression and relapse rates in clinical trials. The problem with this approach is that the population in clinical trials is a selected group of patients, which has the potential to bias results. A better method for extrapolation is to use epidemiologic data. The objective of this study is to incorporate natural history data for MS into a previously presented cost-utility model and to compare the two methods of extrapolation.


METHODS
Clinical trial data were used to model disease progression during the first 3 years in the model. To extrapolate beyond the trial (10 years), data on progression of disability were available from a geographically based epidemiologic study of the natural history of MS in Canada. There were 568 patients who had converted to SPMS during the follow-up that were included in the data set. Mean costs and utilities for each Markov state were calculated from a population-based cross-sectional study in Sweden.


RESULTS
The extrapolation using clinical trial data appears to have underestimated the progression of disability in the long term and thus also the potential benefit of treatment. Using the epidemiologic data, the incremental cost per QALY is SEK 257,000 (US $25,700; US $1 = SEK 10; November 2000) when all costs (direct, informal care, and indirect) are included (discounted 3%). This compares to SEK 342,000 in the previous model. The lower cost-effectiveness ratio is mostly due to a larger QALY gain with treatment than in the previous model (0.217 compared with 0.162).


CONCLUSIONS
Cost-effectiveness analysis in SPMS requires that the effect of treatment beyond clinical trials be included. The method of extrapolation clearly affects the results, and when available, epidemiologic data should be used. Using the longitudinal data from Canada, the cost-utility ratios for IFNB-1b in the treatment of SPMS appear well within the acceptable range.
Kobelt
Gisela
G
Stockholm School of Economics.
Jönsson
Linus
L
Miltenburger
Carolin
C
Jönsson
Bengt
B
D000276:Adjuvants, Immunologic / Q000191:economics* / Q000627:therapeutic use*; D000328:Adult; D002170:Canada / Q000453:epidemiology; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000191:economics* / Q000627:therapeutic use*; D008297:Male; D008390:Markov Chains; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology / Q000503:physiopathology; D017063:Outcome Assessment, Health Care; D019057:Quality-Adjusted Life Years; D012189:Retrospective Studies; D013673:Technology Assessment, Biomedical
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a